LobbyingSenior Care Pharmacy Coalition lobbying by quarter
Senior Care Pharmacy Coalition's latest lobbying report covers Q2 2026, at $560K. The four quarters Q3 2025–Q2 2026 total $2.4M. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Senior Care Pharmacy Coalition
- Latest quarter
- $560K
- Q2 2026 · 4 reports
- Last 12 months
- $2.4M
- Last 4 quarters
- vs last quarter
- −18.8%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $520K | 4 |
| Q1 2023 | $500K | 4 |
| Q2 2023 | $500K | 4 |
| Q3 2023 | $500K | 4 |
| Q4 2023 | $500K | 4 |
| Q1 2024 | $510K | 4 |
| Q2 2024 | $510K | 4 |
| Q3 2024 | $530K | 4 |
| Q4 2024 | $530K | 4 |
| Q1 2025 | $350K | 4 |
| Q2 2025 | $290K | 3 |
| Q3 2025 | $480K | 4 |
| Q4 2025 | $660K | 4 |
| Q1 2026 | $690K | 4 |
| Q2 2026 | $560K | 4 |
Policy issues the reports name
- Health issues40 reports
- Medicare and Medicaid34 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES58 reports
- SENATE58 reports
- Centers For Medicare and Medicaid Services (CMS)31 reports
- Health & Human Services, Dept of (HHS)16 reports
- White House Office8 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseSenior Care Pharmacy Coalition | $4M | 15 quarters |
| King & Spalding | $1.4M | 15 quarters |
| BGR Government Affairs | $1.3M | 15 quarters |
| Lincoln Policy Group | $750K | 10 quarters |
| The Smith-Free Group | $160K | 4 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CHARLIE CHAPMAN | Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committee; LA, House Budget Committee; Staff Asst, House Ways and Means Committee; Intern, House Ways and Means Committee | Q2 2026 |
| CHRIS KELLY | Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn | Q2 2026 |
| EMILY DUHOVNY SILVERBERG | Apr 2025-May 2026 Deputy Chief of Staff/Legislative Director Jan 2021-Apr 2025 Legislative Director May 2014-Jan 2020 Senior Legislative/Policy Advisor Jan 2013-April 2018 Staff/Legislative Assistant Sep 2012-Jan 2013 Congressional Intern. | Q2 2026 |
| JOHN STONE | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C | Q2 2026 |
| LOREN MONROE | Leg. Aide to Sen. Pete Domenici | Q2 2026 |
| RAGHAV AGGARWAL | Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior | Q2 2026 |
| ROBB WALTON | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes | Q2 2026 |
| ROBERT WOOD | Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug | Q2 2026 |
| SHARA SIEGEL | Food and Drug Administration, Public Health Advisor (March 2024-June 2025) | Q2 2026 |
| TODD TUTEN | Jan 2025-Mar 2026 U.S. Senate Committee on Health, Education, Labor, & Pensions, Chief Counsel May 2025-Mar 2026, Senior Health Counsel Jan 2025-May 2025 [House Lobbying Only] | Q2 2026 |
| NICK IAROSSI | N/A | Q1 2026 |
| SCOTT DZIENGELSKI | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017) | Q1 2026 |
| DANIEL FARMER | Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space | Q3 2025 |
| REMY LEIGH BRIM MASON | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz | Q4 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | The Smith-Free Group | $60K |
| 07/20for Q2 | BGR Government Affairs | $90K |
| 07/19for Q2 | King & Spalding | $90K |
| 07/17for Q2 | In-house | $320K |
| 04/20for Q1 | King & Spalding | $90K |
| 04/20for Q1 | The Smith-Free Group | $60K |
| 04/20for Q1 | In-house | $450K |
| 04/20for Q1 | BGR Government Affairs | $90K |
| 01/20for Q4 2025 | The Smith-Free Group | $30K |
| 01/20for Q4 2025 | The Smith-Free Group | $30K |
| 01/20for Q4 2025 | In-house | $450K |
| 01/20for Q4 2025 | BGR Government Affairs | $90K |
| 01/19for Q4 2025 | King & Spalding | $90K |
| 25/10/20for Q3 2025 | In-house | $290K |
| 25/10/20for Q3 2025 | The Smith-Free Group | $10K |
| 25/10/20for Q3 2025 | BGR Government Affairs | $90K |
| 25/10/19for Q3 2025 | King & Spalding | $90K |
| 25/09/26for Q3 2025 | The Smith-Free Group | Under $5,000 |
| 25/07/21for Q2 2025 | King & Spalding | $90K |
| 25/07/21for Q2 2025 | BGR Government Affairs | $90K |